LT3687996T - Pirolotriazino darinių druskos, naudingos kaip tam inhibitoriai - Google Patents

Pirolotriazino darinių druskos, naudingos kaip tam inhibitoriai

Info

Publication number
LT3687996T
LT3687996T LTEPPCT/US2018/052925T LTUS2018052925T LT3687996T LT 3687996 T LT3687996 T LT 3687996T LT US2018052925 T LTUS2018052925 T LT US2018052925T LT 3687996 T LT3687996 T LT 3687996T
Authority
LT
Lithuania
Prior art keywords
salts
derivatives useful
pyrrolotriazine derivatives
tam inhibitors
tam
Prior art date
Application number
LTEPPCT/US2018/052925T
Other languages
English (en)
Inventor
Zhongjiang JIA
Yongzhong Wu
Yongchun Pan
Jiacheng Zhou
Qun Li
Original Assignee
Incyte Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corporation filed Critical Incyte Corporation
Publication of LT3687996T publication Critical patent/LT3687996T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
LTEPPCT/US2018/052925T 2017-09-27 2018-09-26 Pirolotriazino darinių druskos, naudingos kaip tam inhibitoriai LT3687996T (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762564070P 2017-09-27 2017-09-27
US201862714196P 2018-08-03 2018-08-03
PCT/US2018/052925 WO2019067594A1 (en) 2017-09-27 2018-09-26 SALTS OF PYRROLOTRIAZINE DERIVATIVES USEFUL AS TAM INHIBITORS

Publications (1)

Publication Number Publication Date
LT3687996T true LT3687996T (lt) 2022-01-10

Family

ID=63794769

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/US2018/052925T LT3687996T (lt) 2017-09-27 2018-09-26 Pirolotriazino darinių druskos, naudingos kaip tam inhibitoriai

Country Status (32)

Country Link
US (3) US10633387B2 (lt)
EP (2) EP3988552A1 (lt)
JP (1) JP2020535168A (lt)
KR (1) KR20200088308A (lt)
CN (1) CN111386273A (lt)
AU (2) AU2018342471B2 (lt)
BR (1) BR112020006145A2 (lt)
CA (1) CA3077308A1 (lt)
CL (2) CL2020000791A1 (lt)
CO (1) CO2020005009A2 (lt)
CR (1) CR20200179A (lt)
CY (1) CY1124952T1 (lt)
DK (1) DK3687996T3 (lt)
EC (1) ECSP20021655A (lt)
ES (1) ES2904458T3 (lt)
GE (1) GEP20227429B (lt)
HU (1) HUE057190T2 (lt)
IL (1) IL273579A (lt)
JO (1) JOP20200081A1 (lt)
LT (1) LT3687996T (lt)
MA (1) MA50655B1 (lt)
MD (1) MD3687996T2 (lt)
MX (1) MX2020003375A (lt)
PE (1) PE20210002A1 (lt)
PH (1) PH12020550143A1 (lt)
PL (1) PL3687996T3 (lt)
PT (1) PT3687996T (lt)
RS (1) RS62872B1 (lt)
SG (1) SG11202002821UA (lt)
SI (1) SI3687996T1 (lt)
TW (1) TWI821200B (lt)
WO (1) WO2019067594A1 (lt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017035366A1 (en) 2015-08-26 2017-03-02 Incyte Corporation Pyrrolopyrimidine derivatives as tam inhibitors
TWI828027B (zh) 2016-03-28 2024-01-01 美商英塞特公司 作為tam抑制劑之吡咯并三嗪化合物
JP7332472B2 (ja) 2016-12-22 2023-08-23 ノバルティス アーゲー Ｎｍｄａ受容体モジュレーターおよびその使用
KR20200088308A (ko) * 2017-09-27 2020-07-22 인사이트 코포레이션 Tam 억제제로서 유용한 피롤로트리아진 유도체의 염
WO2020006408A1 (en) 2018-06-29 2020-01-02 Incyte Corporation Formulations of an axl/mer inhibitor
LT3830092T (lt) 2018-08-03 2023-09-11 Novartis Ag Heteroaromatiniai nmda receptorių moduliatoriai ir jų panaudojimai
KR20230017165A (ko) 2020-03-06 2023-02-03 인사이트 코포레이션 Axl/mer 및 pd-1/pd-l1 억제제를 포함하는 병행 요법
WO2022007921A1 (zh) * 2020-07-10 2022-01-13 北京范恩柯尔生物科技有限公司 三嗪类化合物及其组合物和用途
CN115028648A (zh) * 2021-03-03 2022-09-09 武汉誉祥医药科技有限公司 三并环化合物及其药物组合物和应用
WO2023286719A1 (ja) * 2021-07-13 2023-01-19 日本曹達株式会社 ウラシル化合物の製造方法

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ2002934A3 (cs) 1999-09-17 2002-07-17 Abbott Gmbh & Co. Kg Inhibitory kinázy jako terapeutická činidla
AU1560802A (en) 2000-06-28 2002-01-08 Smithkline Beecham Plc Wet milling process
WO2004035580A1 (en) 2002-10-21 2004-04-29 Aprea Ab Reactivation of wild type p53 in human tumour cells by a low molecular weight compound
US20050203063A1 (en) 2003-09-12 2005-09-15 Raymond Deshaies Proteasome pathway inhibitors and related methods
UY28931A1 (es) 2004-06-03 2005-12-30 Bayer Pharmaceuticals Corp Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
TW200613306A (en) 2004-07-20 2006-05-01 Osi Pharm Inc Imidazotriazines as protein kinase inhibitors
UY29177A1 (es) 2004-10-25 2006-05-31 Astex Therapeutics Ltd Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
JP5335432B2 (ja) 2005-11-17 2013-11-06 オーエスアイ・フアーマシユーテイカルズ・エル・エル・シー 縮合２環系ｍＴＯＲ阻害剤
PE20070855A1 (es) 2005-12-02 2007-10-14 Bayer Pharmaceuticals Corp Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
KR101461680B1 (ko) 2005-12-02 2014-11-19 바이엘 헬스케어 엘엘씨 과다-증식성 장애 및 맥관형성과 관련된 질환의 치료에유용한 치환된 4-아미노-피롤로트리아진 유도체
DK2343299T3 (en) 2005-12-13 2016-01-18 Incyte Holdings Corp Heteroberl-substituted pyrrolo [2,3-b] pyridines and pyrrolo [2,3-b] pyrimidines as Janus kinase inhibitors
US7601713B2 (en) 2005-12-15 2009-10-13 Rigel Pharmaceuticals, Inc. Kinase inhibitors and their uses
AR060432A1 (es) 2006-04-12 2008-06-18 Vertex Pharma Tetrahidropteridinas utiles como inhibidores de las proteinas quinasas
US20090253718A1 (en) 2006-04-25 2009-10-08 Astex Therapeutics Limited Pharmaceutical Compounds
US8097630B2 (en) 2006-10-10 2012-01-17 Rigel Pharmaceuticals, Inc. Pinane-substituted pyrimidinediamine derivatives useful as Axl inhibitors
JP5406725B2 (ja) 2006-12-14 2014-02-05 バーテックス ファーマシューティカルズ インコーポレイテッド タンパク質キナーゼ阻害剤として有用な化合物
CA2710046C (en) 2006-12-29 2016-02-09 Rigel Pharmaceuticals, Inc. N3-heteroaryl substituted triazoles and n5-heteroaryl substituted triazoles useful as axl inhibitors
WO2008083353A1 (en) 2006-12-29 2008-07-10 Rigel Pharmaceuticals, Inc. Bicyclic aryl and bicyclic heteroaryl substituted triazoles useful as axl inhibitors
US7709482B2 (en) 2006-12-29 2010-05-04 Rigel Pharmaceuticals, Inc. Polycyclic heteroaryl substituted triazoles useful as Axl inhibitors
WO2008098139A2 (en) 2007-02-07 2008-08-14 The Regents Of The University Of Colorado Axl tyrosine kinase inhibitors and methods of making and using the same
JP5380447B2 (ja) 2007-08-15 2014-01-08 バーテックス ファーマシューティカルズ インコーポレイテッド 増殖性疾患の処置のための、ヒトタンパク質キナーゼｐｌｋ１ないしｐｌｋ４の阻害剤としての４−（９−（３，３−ジフルオロシクロペンチル）−５，７，７−トリメチル−６−オキソ−６，７，８，９−テトラヒドロ−５ｈ−ピリミド［４，５−ｂ［１，４］ジアゼパン−２−イルアミノ］−３−メトキシベンザミド誘導体
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
JP2011500778A (ja) 2007-10-25 2011-01-06 アストラゼネカ・アクチエボラーグ ピリジン及びピラジン誘導体−０８３
EP2205592B1 (en) 2007-10-26 2013-05-08 Rigel Pharmaceuticals, Inc. Polycyclic aryl substituted triazoles and polycyclic heteroaryl substituted triazoles useful as axl inhibitors
WO2009085185A1 (en) 2007-12-19 2009-07-09 Amgen Inc. Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
AR070127A1 (es) 2008-01-11 2010-03-17 Novartis Ag Pirrolo - pirimidinas y pirrolo -piridinas
US9206130B2 (en) 2008-04-16 2015-12-08 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Quinoline derivatives as AXL kinase inhibitors
CN102076690A (zh) 2008-06-23 2011-05-25 维泰克斯制药公司 蛋白激酶抑制剂
ES2537480T3 (es) 2008-07-09 2015-06-08 Rigel Pharmaceuticals, Inc. Triazoles sustituidos con heteroarilo policíclicos útiles como inhibidores de Axl
CA2730251C (en) 2008-07-09 2016-08-09 Rigel Pharmaceuticals, Inc. Bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors
US20120230991A1 (en) 2008-07-29 2012-09-13 Douglas Kim Graham Methods and compounds for enhancing anti-cancer therapy
WO2010025073A1 (en) 2008-08-28 2010-03-04 Takeda Pharmaceutical Company Limited Dihydroimidazo [ 1, 5-f] pteridines as polo-like kinase inhibitors
EP2376491B1 (en) 2008-12-19 2015-03-04 Cephalon, Inc. Pyrrolotriazines as alk and jak2 inhibitors
CN102307875A (zh) 2009-02-09 2012-01-04 苏伯俭股份有限公司 吡咯并嘧啶基axl激酶抑制剂
EP2424368B1 (en) 2009-04-29 2014-12-31 Locus Pharmaceuticals, Inc. Pyrrolotriazine compounds
EP2432555B1 (en) 2009-05-22 2014-04-30 Incyte Corporation N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
CN104945420A (zh) 2009-06-29 2015-09-30 因塞特公司 作为pi3k抑制剂的嘧啶酮类
US9249145B2 (en) 2009-09-01 2016-02-02 Incyte Holdings Corporation Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
MX2012003476A (es) 2009-09-25 2012-06-19 Vertex Pharma Metodos para preparar derivados de pirimidina utiles como inhibidores de proteina cinasa.
EP2311809A1 (en) 2009-10-16 2011-04-20 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Quinolinyloxyphenylsulfonamides
US8604217B2 (en) 2009-11-12 2013-12-10 Selvita S.A. Compound, a process for its preparation, a pharmaceutical composition, use of a compound, a method for modulating or regulating serine/threonine kinases and a serine/threonine kinases modulating agent
US8680108B2 (en) 2009-12-18 2014-03-25 Incyte Corporation Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors
MX364636B (es) 2010-03-10 2019-05-03 Incyte Corp Derivados de piperidin-4-il azetidina como inhibidores de janus cinasa 1 (jak1).
JP5752232B2 (ja) 2010-03-31 2015-07-22 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ プロテインキナーゼ阻害剤としての置換ピロロトリアジン化合物
CA2761074A1 (en) 2010-05-05 2011-11-10 Vertex Pharmaceuticals Incorporated 4 substituted pyrazolopyrimidines useful as pkc-theta inhibitors
EP2423208A1 (en) 2010-08-28 2012-02-29 Lead Discovery Center GmbH Pharmaceutically active compounds as Axl inhibitors
WO2012048129A2 (en) 2010-10-08 2012-04-12 Elan Pharmaceuticals, Inc. Inhibitors of polo-like kinase
ITRM20100537A1 (it) 2010-10-12 2012-04-12 Consiglio Nazionale Ricerche Aptamero inibitore del recettore tirosina chinasi axl per uso in terapia
AU2011329734B2 (en) 2010-11-19 2015-05-28 Incyte Holdings Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
JP5917544B2 (ja) 2010-11-19 2016-05-18 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｊａｋ阻害剤としての複素環置換ピロロピリジンおよびピロロピリミジン
WO2012087881A1 (en) 2010-12-20 2012-06-28 Incyte Corporation N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
US9133162B2 (en) 2011-02-28 2015-09-15 Sunshine Lake Pharma Co., Ltd. Substituted quinoline compounds and methods of use
MY161199A (en) 2011-03-23 2017-04-14 Amgen Inc Fused tricyclic dual inhibitors of cdk 4/6 and flt3
BR112013025387B1 (pt) 2011-04-01 2021-07-27 University Of Utah Research Foundation Compostos análogos substituídos da n-fenilpirimidin-2-amina como inibidores da quinase axl, uso dos ditos compostos para o tratamento de um distúrbio de proliferação celular descontrolada, bem como kit compreendendo ditos compostos
KR20140040819A (ko) 2011-06-20 2014-04-03 인사이트 코포레이션 Ｊａｋ 저해제로서의 아제티디닐 페닐, 피리딜 또는 피라지닐 카르복스아미드 유도체
MX2013014315A (es) 2011-07-01 2014-01-31 Bayer Pharma AG Pirrolotriazinas sustituidas con hidroximetilarilo y sus usos.
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
PE20181272A1 (es) 2011-09-02 2018-08-03 Incyte Holdings Corp Heterociclilaminas como inhibidores de pi3k
CN102408411B (zh) 2011-09-19 2014-10-22 北京康辰药业股份有限公司 一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用
AU2012318896B2 (en) 2011-10-03 2017-03-02 The University Of North Carolina At Chapel Hill Pyrrolopyrimidine compounds for the treatment of cancer
PL2780338T3 (pl) 2011-11-14 2017-04-28 Ignyta, Inc. Pochodne uracylu jako inhibitory kinaz AXL i c-MET
WO2013085802A1 (en) 2011-12-06 2013-06-13 Merck Sharp & Dohme Corp. Pyrrolopyrimidines as janus kinase inhibitors
DK2810937T3 (en) 2012-01-31 2017-03-13 Daiichi Sankyo Co Ltd PYRIDONE DERIVATIVES
WO2013162061A1 (ja) 2012-04-26 2013-10-31 第一三共株式会社 二環性ピリミジン化合物
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
US10227357B2 (en) 2012-09-06 2019-03-12 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
CN104995192A (zh) 2012-09-26 2015-10-21 加利福尼亚大学董事会 Ire1的调节
WO2014062774A1 (en) 2012-10-17 2014-04-24 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
SG10201703533VA (en) 2012-11-01 2017-06-29 Incyte Corp Tricyclic fused thiophene derivatives as jak inhibitors
CN104936963B (zh) 2012-11-20 2017-11-28 普罗齐纳斯有限公司 作为蛋白激酶抑制剂的硫醚衍生物
WO2014109858A1 (en) 2013-01-14 2014-07-17 Amgen Inc. Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
TW201522337A (zh) 2013-03-12 2015-06-16 Arqule Inc 經取代之三環吡唑並－嘧啶化合物類
TWI649308B (zh) 2013-07-24 2019-02-01 小野藥品工業股份有限公司 喹啉衍生物
EP3067356B1 (en) 2013-11-08 2018-07-04 ONO Pharmaceutical Co., Ltd. Pyrrolo pyrimidine derivative
JP6162904B2 (ja) 2014-02-03 2017-07-12 カディラ ヘルスケア リミティド 新規複素環式化合物
WO2016097918A1 (en) 2014-12-18 2016-06-23 Pfizer Inc. Pyrimidine and triazine derivatives and their use as axl inhibitors
US9840503B2 (en) 2015-05-11 2017-12-12 Incyte Corporation Heterocyclic compounds and uses thereof
WO2017027717A1 (en) 2015-08-12 2017-02-16 Incyte Corporation Bicyclic fused pyrimidine compounds as tam inhibitors
WO2017035366A1 (en) 2015-08-26 2017-03-02 Incyte Corporation Pyrrolopyrimidine derivatives as tam inhibitors
US20180296561A1 (en) 2015-10-07 2018-10-18 The University Of North Carolina At Chapel Hill The Methods For Treatment Of Tumors
CA3000803C (en) 2015-10-13 2020-03-24 Nihon Nohyaku Co., Ltd. Oxime group-containing condensed heterocyclic compound or salt thereof, agricultural and horticultural insecticide comprising the compound, and method for using the insecticide
US9695150B2 (en) 2015-11-14 2017-07-04 Calitor Sciences, Llc Crystalline form of a substituted quinoline compound and pharmaceutical compositions thereof
US9920033B2 (en) 2015-11-14 2018-03-20 Calitor Sciences, Llc Crystalline form of a substituted quinoline compound and pharmaceutical compositions thereof
TWI828027B (zh) 2016-03-28 2024-01-01 美商英塞特公司 作為tam抑制劑之吡咯并三嗪化合物
CN109414410B (zh) 2016-04-22 2022-08-12 因赛特公司 Lsd1抑制剂的制剂
WO2017223414A1 (en) * 2016-06-24 2017-12-28 Incyte Corporation HETEROCYCLIC COMPOUNDS AS PI3K-γ INHIBITORS
JOP20170153A1 (ar) 2016-07-15 2019-01-30 Lilly Co Eli نظائر urocortin-2 جديدة معدلة بحمض دهني لعلاج داء السكري وأمراض الكلى المزمنة
RS63928B1 (sr) 2016-07-15 2023-02-28 Ionis Pharmaceuticals Inc Jedinjenja i metode za modulaciju smn2
KR20200088308A (ko) 2017-09-27 2020-07-22 인사이트 코포레이션 Tam 억제제로서 유용한 피롤로트리아진 유도체의 염
WO2020006408A1 (en) * 2018-06-29 2020-01-02 Incyte Corporation Formulations of an axl/mer inhibitor

Also Published As

Publication number Publication date
CO2020005009A2 (es) 2020-05-29
WO2019067594A1 (en) 2019-04-04
EP3687996A1 (en) 2020-08-05
ECSP20021655A (es) 2020-07-31
HUE057190T2 (hu) 2022-04-28
JOP20200081A1 (ar) 2020-04-30
ES2904458T3 (es) 2022-04-05
US20220227770A1 (en) 2022-07-21
CA3077308A1 (en) 2019-04-04
AU2018342471B2 (en) 2023-08-24
PH12020550143A1 (en) 2020-12-07
MA50655A (fr) 2021-06-02
US11104682B2 (en) 2021-08-31
SI3687996T1 (sl) 2022-04-29
SG11202002821UA (en) 2020-04-29
PT3687996T (pt) 2022-01-21
IL273579A (en) 2020-05-31
TW201920186A (zh) 2019-06-01
EP3687996B1 (en) 2021-11-03
CY1124952T1 (el) 2023-01-05
PL3687996T3 (pl) 2022-02-21
RS62872B1 (sr) 2022-02-28
TWI821200B (zh) 2023-11-11
GEP20227429B (en) 2022-10-25
AU2018342471A1 (en) 2020-04-23
CN111386273A (zh) 2020-07-07
US20190112313A1 (en) 2019-04-18
CL2022001014A1 (es) 2022-11-18
CL2020000791A1 (es) 2020-09-25
CR20200179A (es) 2020-11-02
MD3687996T2 (ro) 2022-04-30
DK3687996T3 (da) 2022-01-10
BR112020006145A2 (pt) 2020-10-20
US20200347065A1 (en) 2020-11-05
MX2020003375A (es) 2020-08-03
KR20200088308A (ko) 2020-07-22
US10633387B2 (en) 2020-04-28
MA50655B1 (fr) 2021-11-30
EP3988552A1 (en) 2022-04-27
JP2020535168A (ja) 2020-12-03
AU2023270198A1 (en) 2023-12-14
PE20210002A1 (es) 2021-01-05

Similar Documents

Publication Publication Date Title
IL273579A (en) Salts of pyrrolothrizine compounds used as tem inhibitors.
IL261957A (en) Pyrrolotriazine compounds as TAM inhibitors
SG10202110874TA (en) Novel heterocyclic derivatives useful as shp2 inhibitors
TWI560185B (en) Acid addition salt of trk inhibitor compound
ZA201700386B (en) Heteroaryl compounds useful as inhibitors of sumo activating enzyme
EP3312180A4 (en) Use of pteridinone derivative serving as egfr inhibitor
EP3257857A4 (en) Substituted amino six-membered saturated heterocyclic fat used as long-acting dpp-iv inhibitor
IL275195A (en) History of pyrrole as ACC inhibitors
IL269695A (en) Compounds useful as ALCAT 1 inhibitors
HK1253572A1 (zh) 作為tnap抑制劑的吡啶並噁嗪酮化合物
HK1252767A1 (zh) 作為eaat3抑制劑的吡唑-吡啶衍生物
SG11202002267UA (en) Compounds useful as inhibitors of isoprenylcysteine carboxyl methyltransferase